Physician profile
Anna Teotico
NPI 1629288725
$3,725.44
in general payments reported to CMS, 2019-2025
31 companies · $710 in 2025
The $710 reported for 2025 was more than what 79% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $621 · 2022: $241 · 2023: $924 · 2024: $1,230 · 2025: $710.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,407 · Education: $457.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,406.54 |
| Education | $456.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $474.68 | 2021-2024 | Imbruvica, Darzalex, Tecvayli |
| Beigene USA, INC. | $378.88 | 2023-2025 | Brukinsa |
| Genentech USA, INC. | $313.06 | 2022-2025 | Venclexta, Polivy |
| Abbvie INC. | $309.02 | 2021-2025 | |
| Celgene Corporation | $260.08 | 2021-2024 | Reblozyl |
| Astellas Pharma US INC | $192.98 | 2025 | |
| Incyte Corporation | $187.00 | 2021-2024 | Jakafi, Monjuvi, Pemazyre |
| Glaxosmithkline, LLC. | $158.19 | 2023-2025 | Ojjaara |
| Novartis Pharmaceuticals Corporation | $147.96 | 2023-2025 | |
| Daiichi Sankyo INC. | $140.79 | 2024-2025 | Vanflyta |
| Amgen INC. | $136.30 | 2021-2023 | Kyprolis |
| Pharmacyclics LLC, An Abbvie Company | $120.41 | 2021-2023 | Epkinly, Imbruvica |
| Genmab U.S., INC. | $110.52 | 2024-2025 | Epkinly |
| Beone Medicines USA, INC. | $107.87 | 2025 | Brukinsa |
| Takeda Pharmaceuticals U.S.A., INC. | $102.48 | 2022-2024 | Iclusig, Ninlaro |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kite Pharma, INC. | $73.10 | 2023-2025 | Yescarta |
| Secura Bio, INC. | $66.56 | 2024 | Copiktra |
| Merck Sharp & Dohme LLC | $63.01 | 2023-2024 | Keytruda, Dificid, Prevymis |
| Rigel Pharmaceuticals, INC. | $61.73 | 2024 | Tavalisse, Rezlidhia |
| Jazz Pharmaceuticals INC. | $46.80 | 2021-2024 | |
| Seagen INC. | $46.05 | 2022-2023 | Adcetris |
| Pfizer INC. | $38.01 | 2025 | |
| Sobi, INC | $31.45 | 2024 | |
| Pharmaessentia USA Corporation | $25.59 | 2024 | Besremi |
| Servier Pharmaceuticals LLC | $24.29 | 2021 | |
| Morphosys, US INC. | $23.50 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $19.38 | 2025 | Calquence |
| Eisai INC. | $18.43 | 2025 | |
| Azurity Pharmaceuticals, INC. | $16.42 | 2025 | Danziten |
| Regeneron Healthcare Solutions, INC. | $15.85 | 2024 | Libtayo |
| Alexion Pharmaceuticals, INC. | $15.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Teotico listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.